Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIDA Club Drug Research Funding To Jump 40%, Education Effort Underway

This article was originally published in The Tan Sheet

Executive Summary

The National Institute on Drug Abuse is accelerating its research efforts on the risks of "club drugs," including methamphetamine and GHB, through a 40% funding increase. The institute will now dedicate $54 mil. to study the abuse of these substances.

You may also be interested in...



GHB Analog-Containing Product Demand High, NEJM Researchers Report

Extensive industrial use of the GHB analog 1,4-butanediol (BD), in conjunction with the flexibility and anonymity of Internet marketing, "ensures a continued supply that is almost impossible to regulate," researchers say in the Jan. 11 New England Journal of Medicine.

GHB Analog-Containing Product Demand High, NEJM Researchers Report

Extensive industrial use of the GHB analog 1,4-butanediol (BD), in conjunction with the flexibility and anonymity of Internet marketing, "ensures a continued supply that is almost impossible to regulate," researchers say in the Jan. 11 New England Journal of Medicine.

GHB Analog-Containing Product Demand High, NEJM Researchers Report

Extensive industrial use of the GHB analog 1,4-butanediol (BD), in conjunction with the flexibility and anonymity of Internet marketing, "ensures a continued supply that is almost impossible to regulate," researchers say in the Jan. 11 New England Journal of Medicine.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel